Resources

In this Exclusive Interview transcript, Lora K. Heisler talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about using serotonin in the treatment of obesity and type 2 diabetes.

In this Exclusive Interview, Mary de Groot talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about why people with diabetes have higher rates of depression, how depression differs from diabetes distress, and the effect of depression on diabetes management.

In this Exclusive Interview transcript, Mary de Groot talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about why people with diabetes have higher rates of depression, how depression differs from diabetes distress, and the effect of depression on diabetes management.

How important is support for patients who self-manage their diabetes?

Recently a pump user reported a sudden increase in her glucose levels lasting a couple of days. Her blood sugars were elevated to 275-320mg/dL, with no ketones present.  Changing her infusion sets did not help. Nor did rotating to a new injection site or even using a fresh vial of insulin. After reviewing her insulin pump we noticed a symbol on her “home screen” saying that a special feature was running.

In this Exclusive Interview, Sam Engel talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about diabetes drugs in the pipeline at Merck; clinical trials on sitagliptin and ertugliflozin, including the CompoSIT and VERSIS studies; and the problem of "clinical inertia" in intensifying treatment.

In this Exclusive Interview transcript, Sam Engel talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about how clinical inertia affects diabetes treatment; clinical trials on sitagliptin and ertugliflozin, including the CompoSIT and VERSIS studies; and diabetes drugs in the Merck pipeline.

Combination treatment can help improve glucose levels in patients with elevated HbA1Cs.

Gastric bypass surgery is not only for treating obesity.

GLP1-RA and SGLT2i reduce atherosclerotic major cardiovascular events (MACE) to a similar degree in patients with established ASCVD.